What Meladinina Treats: Main Uses and Benefits

Meladinina (Methoxsalen) is commonly used as part of a controlled photochemotherapy setting (PUVA or photopheresis) to support the management of symptoms related to specific, often widespread, chronic skin conditions. The medicine is generally applied when supportive symptom management is appropriate, particularly for conditions marked by increased discomfort or tension.

The therapeutic relevance is aligned with managing symptoms in conditions such as severe, recalcitrant psoriasis, generalized vitiligo, and the skin manifestations of Cutaneous T-cell Lymphoma (CTCL).

---

Clinical Contexts and Benefits

This treatment is applied in conditions where symptoms may intensify temporarily, such as severe psoriasis presenting with heightened manifestations. The approach is used for managing symptoms that interfere with daily functioning, and may assist with easing the overall symptom load related to plaque-type lesions, scaling, and inflammation. For conditions involving loss of skin color, the therapeutic benefit supports the process of repigmentation within the white patches, assisting with maintaining functional stability related to appearance. In palliative contexts, the medicine is used for managing symptoms related to CTCL skin manifestations.

---

Quick Fact: Symptom Management for Chronic Skin Manifestations

Therapeutic Goal	Symptom Domains Addressed	Patient Benefit
Addressing Plaque Symptoms	Thickness, scaling, and inflammation in severe psoriasis.	Contributes to easing the overall symptom load.
Supporting Pigmentary Symptoms	Widespread loss of skin color in generalized vitiligo.	Supports general well-being during symptomatic phases.
Support for Lesion Symptoms	Challenging skin lesions associated with CTCL.	Assists with maintaining functional stability and comfort.

The eligibility for using Meladinina (Methoxsalen) is strictly controlled by regulatory bodies due to its photosensitizing nature, which necessitates the exclusion of specific populations. The medicine is primarily established for use in adults who meet the criteria for severe, recalcitrant psoriasis, generalized vitiligo, or Cutaneous T-cell Lymphoma.

Populations for Whom Use is Contraindicated

Absolute non-eligibility rules, as defined in official labeling, apply to:

• Patients with aphakia (absence of the lens of the eye).
• Individuals with a history of melanoma or invasive squamous cell carcinoma.
• Patients with specific light-sensitive diseases, including lupus erythematosus, albinism, or porphyria.
• Individuals with known hypersensitivity to methoxsalen or other psoralen compounds.

Age-Related and Condition-Specific Restrictions

• Pediatric Population: Safety and efficacy are not established for all pediatric age groups, including children under 12 years for the oral formulation, and adolescents under 18 for the CTCL indication.
• Pregnancy and Lactation: Use during pregnancy is highly restricted (Pregnancy Category D). Use in lactating women is either contraindicated or requires cessation of breastfeeding, as stated in regulatory documents.
• Organ Function: Use in patients with severe hepatic or renal impairment requires special caution and monitoring, as clinical data for the injectable solution in these populations is not established.

The resulting eligibility structure restricts use to patients who possess no formally listed ocular, oncological, or photosensitive contraindications, and who fall within the age and health status parameters for which use has been adequately documented.

Meladinina, which contains the active substance methoxsalen, has documented interactions that fall into two main categories: additive photosensitivity effects and pharmacokinetic effects on other medicines.

Interactions Resulting in Additive Photosensitivity

Concomitant use with other medicinal products known to be photosensitizing agents must be approached with caution or avoided. This includes systemic and topical agents that increase skin sensitivity to light, as co-administration can lead to an increased risk of severe phototoxic reactions.

Furthermore, the consumption of foods and products containing high concentrations of furocoumarin compounds should be restricted while taking this medicine. These substances, found in certain foods such as limes, figs, parsley, and celery, can contribute to the light-sensitizing effect, posing an additive risk of phototoxicity.

Pharmacokinetic Interactions (CYP1A2 Inhibition)

Methoxsalen is classified in official regulatory documentation as a moderate inhibitor of the cytochrome P450 1A2 (CYP1A2) enzyme. This mechanistic action can lead to increased blood concentrations of co-administered medicines that are primarily metabolized by this enzyme (CYP1A2 substrates). When such co-administration is necessary, the regulatory labeling requires careful clinical monitoring for signs of increased drug exposure and toxicity, and the dose of the CYP1A2 substrate medicine may need adjustment.

The following text describes the pharmacodynamic mechanism of Methoxsalen (Meladinina), focusing only on biological targets and physiological consequences.

How Meladinina Works

Photoactivation and DNA Interstrand Cross-linking

The biological activity of Methoxsalen is contingent upon its identity as an obligate photosensitizer, requiring activation by external UVA light (320–400 nm). Once energized, the molecule physically intercalates into cellular DNA and forms irreversible covalent cross-links with pyrimidine bases. This mechanism produces a profound inhibition of DNA synthesis and cellular replication, which is the foundational consequence of reduced cellular replication.

Dual Mechanism: Anti-Proliferation and Immune Modulation

The resulting molecular damage exerts a dual physiological consequence. The blockade of replication slows the rate of proliferation in rapidly dividing skin cells. Furthermore, the DNA damage selectively triggers the programmed death (apoptosis) of inflammatory T-lymphocytes in the skin, contributing to a significant modulation of the localized cutaneous immune cell population.

Stimulation of Melanocyte Activity

In contrast to its inhibitory action on other cells, Methoxsalen's photo-activated mechanism promotes the process of pigmentation. It stimulates the division and activity of melanocytes (pigment-producing cells) and enhances enzymes like tyrosinase. The biological consequence is the increased synthesis and transfer of new melanin pigment within the tissue.

The use of Methoxsalen (Meladinina) is governed by strict, specific protocols, as the medicine functions only when coupled with controlled long-wave ultraviolet A (UVA) light exposure (PUVA or ECP).

Administration Scope

Category	Official Instructions
Route of administration	The medicine is administered via oral capsules, topical solution, or extracorporeal injection into the photopheresis system's processing bag. It is not administered as a direct intravenous injection to the patient.
Dosing schedule	Oral Dosing for Psoriasis is weight-based, ranging from 10 mg to a maximum of 70 mg per treatment session. Extracorporeal Dosing for Cutaneous T-cell Lymphoma (CTCL) is calculated based on the treatment volume, using 0.017 mL of the solution per volume of blood fraction.
Timing in relation to food	Oral capsules must be taken with food or low-fat milk to optimize absorption.
Frequency and Interval	Treatment is limited to two or three times per week, and sessions must be separated by a minimum interval of 48 hours. CTCL treatment via Extracorporeal Photopheresis (ECP) is typically administered on two consecutive days every four weeks.
Age-group rules	Safety and effectiveness for oral and topical use are not established in children under 12 years of age.
Missed-dose rule	If a dose is missed, the associated UVA light exposure session must be rescheduled due to the requirement for precise timing between drug administration and light exposure.

Procedural Structure

Official use begins with the administration of the appropriate dose and form of Methoxsalen. A mandatory time interval (1.5 to 4 hours, depending on the oral form) must then elapse to allow for peak photosensitization before the patient undergoes the scheduled UVA light exposure. The entire procedural structure is governed by the 48-hour minimum interval rule, which dictates the frequency of treatment throughout the required course duration.

Meladinina: Recent Clinical Evidence

Evidence for Use in Severe, Recalcitrant Psoriasis

Research exploring Methoxsalen-based phototherapy consists of data from multiple Randomized Controlled Trials (RCTs) and extensive long-term observational studies. These studies focused on outcomes related to clinical resolution of skin lesions and the tracking of the return of symptoms after the treatment period in adults with severe, refractory disease. Findings from these studies describe patterns observed related to the clearing of lesions and are classified as having a High evidence level.

Evidence for Use in Generalized Vitiligo

Research for this indication consists of data from RCTs, comparative studies, and structured reviews. These trials were applied in research contexts involving patients with widespread skin discoloration that had not responded to initial topical management. The outcomes monitored involved the restoration of skin color (repigmentation). Findings described differences in color restoration patterns when this method was compared to other available therapies. The overall certainty of evidence is categorized as Moderate.

Evidence for Use in Cutaneous T-cell Lymphoma (CTCL)

The evidence base for managing skin manifestations of early-stage CTCL consists of Clinical Trials and follow-up studies of patient cohorts. These studies were applied in research contexts involving fluctuating symptoms in patients with early-stage disease confined primarily to the skin. Research examined outcomes related to the clearing of skin lesions and the time patients remained lesion-free. The body of evidence for the approach in patients with more advanced stages is more limited, and the return of symptoms following treatment completion is an observation recorded in follow-up studies.

Long-Term Research and Research Gaps

Long-term studies track the persistence of measured outcomes over periods up to one year and beyond. However, data are still emerging, and long-term effects are not fully established for all aspects of care. Data for certain groups, such as younger patients or those with specific co-occurring health conditions, remain insufficient. Comparative evidence is lacking in some contexts, and results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

1. Methoxsalen (Oral Route) - Patient Safety and Dosage Information

Common questions about Meladinina (FAQ)

Q: How quickly should I expect to see any effects from Meladinina?

Studies that examined the use of this medicine for conditions like psoriasis indicate that clinical effects, such as the clearing of lesions, are generally observed over a period of several weeks. While some results may begin to appear earlier, official information suggests that typical outcomes may require approximately 6 to 8 weeks of treatment. Individual patient responses may vary widely.

Q: Can Meladinina affect my blood pressure?

Regulatory documents classify changes in blood pressure, specifically hypotension (low blood pressure), as a potential adverse reaction. This finding is based on reports from clinical settings. Official safety information describes the frequency of this reaction as common or less common.

Q: Is there any risk of becoming dependent on Meladinina?

Official records, such as those related to the US Controlled Substances Act, do not categorize Methoxsalen as a controlled substance. This means the medicine is not considered to carry a risk of physical dependence.

Q: Can Meladinina be taken with birth control pills?

The official product information describes Methoxsalen as a moderate inhibitor of the CYP1A2 enzyme. This action can potentially increase the concentration of other medicines that are processed by that enzyme. Furthermore, due to official restrictions concerning use during pregnancy, specific birth control precautions are typically part of the regulatory guidelines for use of this medicine.

Q: Does Meladinina affect the results of any routine lab tests?

Regulatory documents specify the need for monitoring via certain laboratory testing, such as checks of liver and kidney function and complete blood counts. These tests are typically performed to assess the patient's condition during the treatment course.

Q: Does Meladinina have a 'black box' warning in the US or Europe?

The official US prescribing information includes a prominent Boxed Warning, which is sometimes informally called a 'black box' warning. This warning emphasizes the serious risk of burns from improper UVA exposure and the increased long-term risk of skin cancer associated with the treatment. This risk information is presented clearly in the regulatory documentation.

Q: Are there any common misuses of Meladinina that users should be aware of?

Official regulatory documents strictly state that this medicine is restricted to use only as part of a controlled prescription therapy involving specific UVA light exposure. A noted misuse is utilizing the medicine for the purpose of sun tanning, which carries a serious risk of severe phototoxic reactions and increased long-term safety risks.

Q: Does Meladinina interact with herbal supplements like St. John's Wort?

Official regulatory labeling notes the requirement for caution concerning the co-administration of this medicine with other products that are known to increase light sensitivity. These products are broadly classified as photosensitizing agents and may include certain common herbal supplements.

Q: Are weight changes a potential side effect of Meladinina?

Weight changes are not explicitly listed among the known adverse effects in official safety documentation. However, the dose of the oral formulation is often calculated based on the patient's body weight. If a patient experiences a significant weight change, the regulatory documentation notes that dose adjustment may be a consideration.

Q: How long does Meladinina typically stay in your system after stopping?

According to official pharmacokinetic information, the medicine is eliminated from the body relatively quickly, primarily through the urine as inactive compounds. The time it takes for half of the medicine to be cleared from the blood (half-life) is approximately two hours. The drug is generally considered to be cleared from the plasma relatively quickly.

Q: Are there any restrictions on driving or operating machinery while on Meladinina?

Official safety documentation notes that the medicine can cause side effects impacting the central nervous system, such as dizziness and insomnia. Because of the potential for these effects to impair attention or physical coordination, the potential for impaired attention and coordination is noted in regulatory information.

Q: Does Meladinina interact with alcohol?

The official product labeling indicates that the co-administration of this medicine with alcohol, tobacco, or certain foods is a topic specified for consideration in consultation with a healthcare professional. This guidance is in place to manage potential risks arising from various interactions.

Q: What happens if Meladinina is used in a way not described in official labeling?

Official labeling strictly states that this medicine is restricted to use only in accordance with the specific directions for its prescribed therapeutic use. Misuse, such as using the medicine for tanning without the controlled protocol, can lead to severe skin burns (phototoxicity) and significantly increases long-term health risks, including the risk of skin cancer.

Q: Are there any known interactions between Meladinina and caffeine?

Methoxsalen is officially classified as an inhibitor of the CYP1A2 enzyme, which means it can increase the concentration of substances metabolized by that enzyme in the body. Since caffeine is a substance known to be processed by CYP1A2, an interaction is possible, potentially leading to increased caffeine levels.

Q: Is Meladinina considered a controlled substance in any region?

Official records, such as those related to the US Controlled Substances Act, do not categorize Methoxsalen as a controlled substance. This means the medicine is not associated with the regulatory restrictions concerning dependence that apply to controlled substances.

How to Store and Dispose of Meladinina?

Meladinina (Methoxsalen) must be stored according to specific regulatory requirements to maintain its stability.

Storage Requirements

The medicine requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in a closed container and protected from heat, moisture, and direct light to prevent degradation. It is essential to ensure the container is kept from freezing and that the medication is stored safely out of the reach of children.

Disposal Instructions

Outdated or unused medicine should not be kept. Regulatory authorities recommend using drug take-back programs as the preferred disposal method. If a take-back program is unavailable, expired or unused product should be mixed with an undesirable substance, sealed in a container, and disposed of in the household trash, in accordance with local requirements.